| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/28/2005 | US20050163871 Caralluma extract products and processes for making the same |
| 07/28/2005 | US20050163867 Composition and method of treating gastric ulcers in mammals |
| 07/28/2005 | US20050163865 Food supplement embodiments provide the human body nutritional supplements to intake certain neurotransmitter precursor substrates, thereby enabling patients of all ages to self-regulate their ability to quell perturbations to equilibrium and simultaneously to adverse effects |
| 07/28/2005 | US20050163864 Comprises vitamin C, vitamin E, vitamin A (beta-carotene), zinc oxide, and cupric oxide; for promotion of retinal health |
| 07/28/2005 | US20050163862 Suppressing cytokine secretion with such as sodium selenite; by the reduction in extra- and intracellular oxidative stress |
| 07/28/2005 | US20050163859 Injectable compositions for the controlled delivery of pharmacologically active compound |
| 07/28/2005 | US20050163858 active agent has a mean particle size greater than 85 micrometers; controlled-release dosage form; compounded with a histamine-2 antagonist |
| 07/28/2005 | US20050163857 Clarithromycin formulations having improved bioavailability |
| 07/28/2005 | US20050163856 Abuse-resistant sustained-release opioid formulation |
| 07/28/2005 | US20050163855 4-Methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione; solid-dispersing in the polymer and organic solvent or purified water; mixed solution may be spray dried using a spray dryer or granulated using a fluid bed granulator |
| 07/28/2005 | US20050163851 Venlafaxine hydrocloride and sodium chloride; crystals of the sodium chloride are not coated with cellulose acetate butyrate; less conducive to producing drug-drug interactions between the first drug and venlafaxine; drug is not pseudoephedrine or oxybutynin |
| 07/28/2005 | US20050163850 Administration of levodopa and carbidopa |
| 07/28/2005 | US20050163849 Compositions and dosage forms for enhanced absorption of iron |
| 07/28/2005 | US20050163848 complexed with transport moiety comprising a lauryl sulfate salt; complex provides an enhanced absorption of the drug in the lower gastrointestinal tract; to control seizures or neuropathic pain with once daily administration |
| 07/28/2005 | US20050163847 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
| 07/28/2005 | US20050163843 release-retarding material does not comprise hydroxpropyl methylcellulose; Controlled-release formulations, such as longer acting formulations that can be administered once daily or even less frequently |
| 07/28/2005 | US20050163842 Rosiglitazone and metformin formulations |
| 07/28/2005 | US20050163841 to controllably deliver orally a drug at a substantially zero order delivery rate a during a window; improved oral absorption |
| 07/28/2005 | US20050163840 Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| 07/28/2005 | US20050163839 Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| 07/28/2005 | US20050163838 Effervescent oral opiate dosage forms and methods of administering opiates |
| 07/28/2005 | US20050163837 Rosiglitazone formulations |
| 07/28/2005 | US20050163835 Gefitinib or salt with and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether; increased absorption and/or bioavailability and may reduce inter-patient variability; prevents precipitation in higher pH upper GI |
| 07/28/2005 | US20050163834 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| 07/28/2005 | US20050163831 Patch for transdermal administration |
| 07/28/2005 | US20050163828 increased hardness, reduced tackiness and improved handling characteristics; having a weight no greater than 1 gram |
| 07/28/2005 | US20050163822 Biodegradable bio-absorbable material for clinical practice and method for producing the same |
| 07/28/2005 | US20050163817 Biomatrix structural containment and fixation systems and methods of use thereof |
| 07/28/2005 | US20050163811 highly effective, non-oily solution for facilitating hair growth that comprises a high concentration of Minoxidil, that is not cosmetically unattractive when applied to a treatment area and that does not cause skin irritation in the treatment area |
| 07/28/2005 | US20050163804 Containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus; Japanese encephalitis virus (JEV), West Nile virus (WNV) or related flaviviruses |
| 07/28/2005 | US20050163801 Method of inducing apoptosis and compositions therefor |
| 07/28/2005 | US20050163794 Immunological herpes simplex virus antigens and methods for use thereof |
| 07/28/2005 | US20050163785 affect cell growth by blocking progression of the cell cycle in G2/M and their use in therapy of cancers which express the antigen |
| 07/28/2005 | US20050163784 cdc42 is a pivotal molecule in tumors and that up- or downregulation of this component can play a role in stopping cancerous outgrowth; activity increased by administering small molecules of non-hydrolyzable GTP analogues of cdc-42 |
| 07/28/2005 | US20050163781 uses of inhibitors against hypoxia-induced genes for the manufacture of a medicament to prevent and/or to suppress post-operative/post-wounding adhesions formation; peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma |
| 07/28/2005 | US20050163778 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/28/2005 | US20050163770 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 07/28/2005 | US20050163759 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of type I and/or type II phosphodiesterases |
| 07/28/2005 | US20050163756 expressing a gene product in the gut of an animal by orally administering a recombinant AAV vector; effective, long-term expression systems; lactase deficiency |
| 07/28/2005 | US20050163751 Synergistic mixture with compounds such as interferon, paclitaxel or P-16; side effect reduction |
| 07/28/2005 | US20050163731 Skin depigmenting compositions comprising adapalene and at least one depigmenting active agent |
| 07/28/2005 | US20050163727 Topical, oral administration; mouthrinses; microbiocides; bactericides; prevents spread of pathogenic oral bacteria, toxins and endotoxins, and resultant inflammatory cytokines and mediators; cardiovascular disease, stroke, atherosclerosis |
| 07/28/2005 | US20050163726 Respiratory disorders; antiinflamatory agents; capsules containing inhalable powder; aerosols |
| 07/28/2005 | US20050163724 Contains steroidal anti-inflammatory drug, carrier (saccharides, sugar alcohols, amino acids), and water |
| 07/28/2005 | US20050163722 Optimised formulation of tobramycin for aerosolization |
| 07/28/2005 | US20050163719 Buccal, polar and non-polar spray containing diazepam |
| 07/28/2005 | US20050163718 Denatonium benzoate, and cardiotoxic compounds, quinacrine, chloroquine, gamma hydroxybutramide, lidocaine; anesthetic is propofol; prevent accidental death |
| 07/28/2005 | US20050163717 Abuse potential reduction in abusable substance dosage form |
| 07/28/2005 | US20050163712 Method for identifying bronchoconstriction relaxing substances |
| 07/28/2005 | US20050163707 Radio labelled monoclonal antibody human milk fat globule1, binds selectively to polymorphic epithelial mucin; Taxotere chemotherapeutic agent; administered in combination |
| 07/28/2005 | DE4243381B4 3(2H)-Pyridazinonderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie diese enthaltende Arzneimittel und ihre Verwendung 3 (2H) -pyridazinone derivatives, processes and intermediates for their preparation and pharmaceutical compositions containing them and their use |
| 07/28/2005 | DE202005004660U1 Medicinal product useful for treating airway diseases comprises a unit dose of a dry powder mixture of tiotropium and a carrier in a moisture-impermeable container suitable for use in an inhaler |
| 07/28/2005 | DE202005001888U1 Antitumor composition comprises interleukin-2 and sodium dodecyl sulfate in the form of microaggregates |
| 07/28/2005 | DE10361944A1 Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung Means for inhibition of virus replication by regulation of protein folding |
| 07/28/2005 | DE10361502A1 Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen Cosmetic or pharmaceutical preparations containing super structure-forming nucleic acid sequences |
| 07/28/2005 | DE10361259A1 Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes Use of rotigotine in the early stages of Parkinson's disease on the prevention of further loss of neurons |
| 07/28/2005 | DE10361258A1 Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson Use of substituted 2-aminotetralines for the preventive treatment of Parkinson's disease |
| 07/28/2005 | DE10361022A1 Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol Topical preparations containing dimethyl sulfoxide and panthenol |
| 07/28/2005 | DE10360924A1 Composition containing metformin, useful as antidiabetic, is formulated as water-soluble granules for administration, after dissolution, through a gastric tube |
| 07/28/2005 | DE10360745A1 Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel New amide compounds with MCH-antagonistic activity and pharmaceutical compositions containing them |
| 07/28/2005 | DE10360592A1 Pflastersystem zur Verabreichung von Antihistaminika Paving system for administration of antihistamines |
| 07/28/2005 | DE10360425A1 Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| 07/28/2005 | DE10359828A1 CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe CHP-gemcitabine combination and their use as anti-tumor agents, particularly anti-metastasis agents |
| 07/28/2005 | DE10359528A1 (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum (S) -2-N-propylamino-5-hydroxytetralin as D3-therapeutic agonistic |
| 07/28/2005 | DE10359153A1 Use of specific triterpene derivatives for systemic treatment of light-induced dermatatis and the long-term consequences of exposure to ultra-violet light |
| 07/28/2005 | DE10358077A1 Verfahren zur Erhöhung der Sensitivität von Tumorzellen A method for increasing the sensitivity of tumor cells |
| 07/28/2005 | DE10206849A1 Phenalenon-Derivate, Verfahren zur Herstellung und Verwendung derselben Phenalenone derivatives, to processes for preparing and using the same |
| 07/28/2005 | DE102004014294A1 Composition containing mixed oxide that includes aluminum or magnesium and branched alkanoic acid, useful for control of microbes, e.g. treating acne or in cleaning compositions |
| 07/28/2005 | DE102004001093A1 Zusammensetzung und Methode einer synergistischen topischen Therapie neuromuskulärer Schmerzen Composition and method of a synergistic topical treatment of neuromuscular pain |
| 07/28/2005 | DE10043321B4 Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and Lactationshemmung |
| 07/28/2005 | CA2584191A1 Formulation for treating obesity and associated metabolic syndrome |
| 07/28/2005 | CA2559352A1 Lipid compositions and use thereof |
| 07/28/2005 | CA2554382A1 Compounds useful in therapy |
| 07/28/2005 | CA2554045A1 Method for treating erectile dysfunction |
| 07/28/2005 | CA2554001A1 Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same |
| 07/28/2005 | CA2553988A1 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
| 07/28/2005 | CA2553985A1 Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
| 07/28/2005 | CA2553953A1 Therapeutic use of quinonoid derivatives of cannabinoids |
| 07/28/2005 | CA2553938A1 Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2 |
| 07/28/2005 | CA2553781A1 Compositions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug |
| 07/28/2005 | CA2553774A1 Novel compositions comprising higher primary alcohols and nicotinic acid and process of preparation thereof |
| 07/28/2005 | CA2553711A1 Reagent for lacrimation examination and method of lacrimation examination |
| 07/28/2005 | CA2553710A1 Abca1 stabilizer |
| 07/28/2005 | CA2553629A1 Combinations of serotonin reuptake inhibitors and imidazoline-i2-agonists |
| 07/28/2005 | CA2553609A1 Methods and compositions for modulating a steroid receptor |
| 07/28/2005 | CA2553329A1 New fused polycyclic compounds |
| 07/28/2005 | CA2553304A1 Perturbed membrane-binding compounds and methods of using the same |
| 07/28/2005 | CA2553289A1 Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors |
| 07/28/2005 | CA2553202A1 Tricyclic benzazepine derivatives as squalene synthase inhibitors used for the treatment of cardiovascular diseases |
| 07/28/2005 | CA2553200A1 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power |
| 07/28/2005 | CA2552965A1 Carboxamide derivative and use thereof |
| 07/28/2005 | CA2552953A1 Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors |
| 07/28/2005 | CA2552887A1 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid |
| 07/28/2005 | CA2552880A1 Muscarinic acetylcholine receptor antagonists |
| 07/28/2005 | CA2552826A1 2-amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase |
| 07/28/2005 | CA2552797A1 Sphingomyelin, intermediates thereof and methods for preparation of same |
| 07/28/2005 | CA2552681A1 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
| 07/28/2005 | CA2552664A1 Methods for treating and preventing hypertension and hypertension-related disorders |
| 07/28/2005 | CA2552663A1 Crystalline forms of rizatriptan benzoate |
| 07/28/2005 | CA2552649A1 Methods, compositions, and devices for embolizing body lumens |